PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
Market Research Reports.biz

Press Release


Receive press releases from Market Research Reports.biz: By Email RSS Feeds:

New Research Report on Rheumatology Therapeutics Market Analysis Done by MarketResearchReports


New Market Research Report Added in MarketResearchReports.Biz Reports Database Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

Albany, NY, December 22, 2012 --(PR.com)-- Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth. The report provides insights into the rheumatology therapeutics market forecasts until 2018 and examines global treatment usage patterns for various rheumatology disorders. It also looks at the geographical distribution of the rheumatology disorders therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) and provides insights into the R&D pipeline and promising future blockbusters until 2018. The report also profiles major biopharmaceutical companies in the segment and analyzes M&A activity and licensing agreements.

The report covers Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE) and gout, as these are most prevalent forms of rheumatologic disease. The global rheumatology therapeutics market was estimated to be worth $17.1 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 9.4% from 2005, and is forecast to grow at a CAGR of 4.8% to $23.8 billion by 2018.

Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) are the major drugs used in rheumatology therapeutics. Enbrel and Humira account for the majority of the market in the US. Enbrels patent is set to expire in October 2012, although this is not expected to have an immediate impact as biosimilars are not predicted to enter the market until 20162017. In March 2011, the Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of SLE and in July 2011, it was approved by the European Medicines Agency (EMA).

Scope

- Data and analysis for the rheumatology therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain and Japan

- Annualized market data for the rheumatology therapeutics market from 2005 to 2011, forecast to 2018

- In-depth analysis of the acute and chronic rheumatology therapeutics markets

- Market data for the geographical and therapeutic landscapes, including size, annual cost of therapy, revenues, and treatment usage patterns for the diseased population, treatment-seeking population, diagnosed population and prescription population

- Key drivers and barriers that have had a significant impact on the market

- Profiles of major biopharmaceutical markets in the rheumatology therapeutics segment, namely AstraZeneca, Eli Lilly, Pfizer, Janssen Biotech and UCB

- Key M&A activity and licensing agreements from 2007 to April 2012 in the rheumatology therapeutics market

To Buy A Copy Of This Report: http://www.marketresearchreports.biz/analysis/155684

For More Information Kindly Contact:
Hemendra Parmar
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
sales at marketResearchReports.biz
Contact Information
Market Research Reports.biz
Hemendra Parmar
+1-518-618-1030
Contact
www.marketresearchreports.biz

Click here to view the list of recent Press Releases from Market Research Reports.biz
Promote Your Business